Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sirolimus Treatment for Newly Diagnosed Primary Acquired Pure Red Cell Aplasia: a Single Center Prospective Study

NCT04470804 is registered in ClinicalTrials.gov with Bing Han as lead sponsor.

NCT NCT04470804
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04470804 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sirolimus Treatment for Newly Diagnosed Primary Acquired Pure Red Cell Aplasia: a Single Center Prospective Study
Lead sponsor
Bing Han
Phase
Phase 4
Overall status
Completed
Start date
July 1, 2020
Completion date
July 31, 2022
Enrollment
56 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pure red cell aplasia, acquired